Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
BY ELEANOR MALONE Executive Summary Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
13 / September 2020
Biotech always needs money – lots of it – and to get that money it must convince investors that there is a good chance of a profitable exit. It would therefore stand to reason that at a time of stock market retraction and a global recessionary environment, the sector would face a funding crunch. However, in both public and private markets, money is flowing into biotech. The world is beset by significant macro issues – from the pandemicrelated supply chain challenges and economic recession to Brexit – but “by and large biotech ignores these: they don’t really drive any material behaviors in biotech,” David Mardle, a UK-based partner in the technology and life sciences practice of global law firm Goodwin, told Scrip.
© Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
